896 related articles for article (PubMed ID: 28490016)
21. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
Drahushuk K; Connell TD; Higgins D
J Neurosci; 2002 Aug; 22(15):6560-9. PubMed ID: 12151535
[TBL] [Abstract][Full Text] [Related]
22. Neuronal and smooth muscle receptors involved in the PACAP- and VIP-induced relaxations of the pig urinary bladder neck.
Hernández M; Barahona MV; Recio P; Benedito S; Martínez AC; Rivera L; García-Sacristán A; Prieto D; Orensanz LM
Br J Pharmacol; 2006 Sep; 149(1):100-9. PubMed ID: 16847435
[TBL] [Abstract][Full Text] [Related]
23. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Busto R; Sánchez-Chapado M; Guijarro LG; Prieto JC
Cell Signal; 1999 Nov; 11(11):813-9. PubMed ID: 10617284
[TBL] [Abstract][Full Text] [Related]
24. Endogenous inhibition of hippocampal LTD and depotentiation by vasoactive intestinal peptide VPAC1 receptors.
Cunha-Reis D; Aidil-Carvalho Mde F; Ribeiro JA
Hippocampus; 2014 Nov; 24(11):1353-63. PubMed ID: 24935659
[TBL] [Abstract][Full Text] [Related]
25. Pituitary adenylate cyclase-activating polypeptide (PACAP) potently dilates middle meningeal arteries: implications for migraine.
Syed AU; Koide M; Braas KM; May V; Wellman GC
J Mol Neurosci; 2012 Nov; 48(3):574-83. PubMed ID: 22766684
[TBL] [Abstract][Full Text] [Related]
26. Pituitary adenylate cyclase-activating polypeptide (PACAP) induces relaxations of peripheral and cerebral arteries, which are differentially impaired by aging.
Vamos Z; Ivic I; Cseplo P; Toth G; Tamas A; Reglodi D; Koller A
J Mol Neurosci; 2014 Nov; 54(3):535-42. PubMed ID: 24939249
[TBL] [Abstract][Full Text] [Related]
27. [Pituitary adenylate cyclase-activating polypeptide].
Gonzalez BJ; Basille M; Vaudry D; Fournier A; Vaudry H
Ann Endocrinol (Paris); 1998 Dec; 59(5):364-405. PubMed ID: 9949891
[TBL] [Abstract][Full Text] [Related]
28. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
29. Nitric oxide and receptors for VIP and PACAP in cutaneous active vasodilation during heat stress in humans.
Kellogg DL; Zhao JL; Wu Y; Johnson JM
J Appl Physiol (1985); 2012 Nov; 113(10):1512-8. PubMed ID: 22961270
[TBL] [Abstract][Full Text] [Related]
30. VIP and PACAP analogs regulate therapeutic targets in high-risk neuroblastoma cells.
de Boisvilliers M; Perrin F; Hebache S; Balandre AC; Bensalma S; Garnier A; Vaudry D; Fournier A; Festy F; Muller JM; Chadéneau C
Peptides; 2016 Apr; 78():30-41. PubMed ID: 26826611
[TBL] [Abstract][Full Text] [Related]
31. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP-receptor type 1 expression in rat and human placenta.
Scaldaferri ML; Modesti A; Palumbo C; Ulisse S; Fabbri A; Piccione E; Frajese G; Moretti C
Endocrinology; 2000 Mar; 141(3):1158-67. PubMed ID: 10698193
[TBL] [Abstract][Full Text] [Related]
32. PAC1- and VPAC2 receptors in light regulated behavior and physiology: Studies in single and double mutant mice.
Hannibal J; Georg B; Fahrenkrug J
PLoS One; 2017; 12(11):e0188166. PubMed ID: 29155851
[TBL] [Abstract][Full Text] [Related]
33. Distinct receptors mediate pituitary adenylate cyclase-activating peptide- and vasoactive intestinal peptide-induced relaxation of rat ileal longitudinal muscle.
Ekblad E; Sundler F
Eur J Pharmacol; 1997 Sep; 334(1):61-6. PubMed ID: 9346329
[TBL] [Abstract][Full Text] [Related]
34. Characterisation of agonist signalling profiles and agonist-dependent antagonism at PACAP-responsive receptors: Implications for drug discovery.
Tasma Z; Siow A; Harris PWR; Brimble MA; Hay DL; Walker CS
Br J Pharmacol; 2022 Feb; 179(3):435-453. PubMed ID: 34612509
[TBL] [Abstract][Full Text] [Related]
35. Pituitary adenylate cyclase activating polypeptide-mediated intracrine signaling in the testicular germ cells.
Li M; Funahashi H; Mbikay M; Shioda S; Arimura A
Endocrine; 2004 Feb; 23(1):59-75. PubMed ID: 15034198
[TBL] [Abstract][Full Text] [Related]
36. Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats.
Giunta S; Castorina A; Bucolo C; Magro G; Drago F; D'Agata V
Peptides; 2012 Sep; 37(1):32-9. PubMed ID: 22721946
[TBL] [Abstract][Full Text] [Related]
37. Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.
Lu J; Piper SJ; Zhao P; Miller LJ; Wootten D; Sexton PM
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897648
[TBL] [Abstract][Full Text] [Related]
38. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems.
Arimura A
Jpn J Physiol; 1998 Oct; 48(5):301-31. PubMed ID: 9852340
[TBL] [Abstract][Full Text] [Related]
39. Evidence for the involvement of VPAC1 and VPAC2 receptors in pressure-induced vasodilatation in rodents.
Fizanne L; Sigaudo-Roussel D; Saumet JL; Fromy B
J Physiol; 2004 Jan; 554(Pt 2):519-28. PubMed ID: 14578481
[TBL] [Abstract][Full Text] [Related]
40. PACAP intraperitoneal treatment suppresses appetite and food intake via PAC1 receptor in mice by inhibiting ghrelin and increasing GLP-1 and leptin.
Vu JP; Goyal D; Luong L; Oh S; Sandhu R; Norris J; Parsons W; Pisegna JR; Germano PM
Am J Physiol Gastrointest Liver Physiol; 2015 Nov; 309(10):G816-25. PubMed ID: 26336928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
